The FDA Approves First Oral Treatment for Postpartum Depression 

padeptofruralhealth
PA_Dept_of_Rural_Health August 16, 2023

The U.S. Food and Drug Administration (FDA) approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a healthcare provider in certain healthcare facilities.

The post The FDA Approves First Oral Treatment for Postpartum Depression  appeared first on Pennsylvania Office of Rural Health.

Categories: My Healthy Pennsylvania, Rural Health PA
padeptofruralhealth
PA_Dept_of_Rural_Health

Related Articles

CDC: Majority of US Pregnancy-Related Deaths Are Preventable

The US has the highest maternal mortality rate among developed countries, and 84% of those pregnancy-related deaths are preventable, according to a new report by the Centers for Disease Control and Prevention (CDC). These shocking statistics can be difficult to digest, especially since the US spends more on healthcare per capita than other industrialized nations. What …
The post CDC: Majority of US Pregnancy-Related Deaths Are Preventable appeared first on Salud America.

salud-america
Salud America October 27, 2022

Texas Extends Postpartum Medicaid Coverage from 60 Days to Year

June 16, 2023 was a big win for low-income Texas families. Gov. Greg Abbot signed House Bill 12, which extends Medicaid health coverage for Texas mothers from just 60 days after giving birth to a full year. This new bill, which is expected to take effect by the end of 2023, has massive potential to …
The post Texas Extends Postpartum Medicaid Coverage from 60 Days to Year appeared first on Salud America.

salud-america
Salud America June 22, 2023

FDA Approves New Drug for Alzheimer’s, But Scientists Divided Over Decision

The U.S. Food and Drug Administration approved a new drug called Aduhelm (aducanumab) to treat Alzheimer’s disease, the most common form of dementia. Many are applauding the drug and are encouraged by the scientific progress in a field that has long had limited treatment options. Alzheimer’s affects over 6.2 million people in the U.S., with …
The post FDA Approves New Drug for Alzheimer’s, But Scientists Divided Over Decision appeared first on Salud America.

salud-america
Salud America June 15, 2021
0 Comments